A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
2 other identifiers
interventional
912
22 countries
192
Brief Summary
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jul 2018
Longer than P75 for phase_3
192 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 25, 2018
CompletedStudy Start
First participant enrolled
July 27, 2018
CompletedFirst Posted
Study publicly available on registry
July 31, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 11, 2021
CompletedResults Posted
Study results publicly available
March 28, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
November 11, 2025
CompletedDecember 3, 2025
November 1, 2025
2.6 years
July 25, 2018
March 1, 2022
November 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Baseline and Week 16
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No inflammatory signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification, no oozing or crusting; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification, no oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.
Baseline and Week 16
Secondary Outcomes (44)
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16
Baseline (last available rolling average before the first dose of study drug) and Week 16
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16
Baseline and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
Baseline (last available rolling average before the first dose of study drug) and Week 4
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2
Baseline and Week 2
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
Baseline (last available rolling average before the first dose of study drug) and Week 1
- +39 more secondary outcomes
Study Arms (3)
Placebo / Upadacitinib
PLACEBO COMPARATORParticipants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.
Upadacitinib 15 mg QD
EXPERIMENTALParticipants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.
Upadacitinib 30 mg QD
EXPERIMENTALParticipants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.
Interventions
Tablets taken orally once a day
Eligibility Criteria
You may qualify if:
- Body weight of ≥ 40 kg at Baseline Visit for participants ≥ 12 and \< 18 years of age
- Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to Baseline and subject meets Hanifin and Rajka criteria
- Active moderate to severe AD defined by Eczema Area and Severity Index (EASI) ≥ 16, validated Investigator's Global Assessment (vIGA) ≥ 3, body surface area (BSA) affected by AD ≥ 10%, and weekly average of daily Worst Pruritus numerical rating scale (NRS) score ≥ 4.
- Candidate for systemic therapy or have recently required systemic therapy for AD
- Documented history (within 6 months prior to Baseline) of inadequate response to topical corticosteroid (TCS) or topical calcineurin inhibitor (TCI) or documented systemic treatment for AD or for whom topical treatments are otherwise medically inadvisable due to side effects or safety risks
You may not qualify if:
- Prior exposure to any Janus kinase (JAK) inhibitor
- Unable or unwilling to discontinue current AD treatments prior to the study
- Requirement of prohibited medications during the study
- Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
- Female subject who is pregnant, breastfeeding, or considering pregnancy during the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AbbVielead
Study Sites (196)
Total Skin and Beauty Derm Ctr /ID# 205129
Birmingham, Alabama, 35205, United States
Medical Dermatology Specialist /ID# 205516
Phoenix, Arizona, 85006-2722, United States
Arizona Research Center, Inc. /ID# 205795
Phoenix, Arizona, 85053-4061, United States
The Dermatology Clinic of Arkansas /ID# 218749
Bryant, Arkansas, 72022-7514, United States
Arkansas Research Trials /ID# 218469
North Little Rock, Arkansas, 72117, United States
Encino Research Center /ID# 207472
Encino, California, 91436, United States
University of California Irvine /ID# 205136
Irvine, California, 92697-1385, United States
Ark Clinical Research /ID# 218193
Long Beach, California, 90806-2325, United States
Keck School of Medicine of USC /ID# 206971
Los Angeles, California, 90033, United States
Wallace Medical Group /ID# 205701
Los Angeles, California, 90056, United States
Child Hosp of Orange County,CA /ID# 205735
Orange, California, 92868, United States
Palmtree Clinical Research Inc. /Id# 206184
Palm Springs, California, 92262, United States
Rady Children's Hospital San Diego /ID# 208244
San Diego, California, 92123, United States
Southern California Derma. Inc /ID# 205734
Santa Ana, California, 92701, United States
Innovative Clinical Research - Lafayette /ID# 208400
Lafayette, Colorado, 80026, United States
New England Research Associates, LLC /ID# 206896
Bridgeport, Connecticut, 06606-1827, United States
Ideal Clinical Research Inc. /ID# 209880
Aventura, Florida, 33180, United States
Skin Care Research, LLC /ID# 207099
Boca Raton, Florida, 33486-2269, United States
Midflorida Clinical Research, Inc. /ID# 213700
Brandon, Florida, 33511-5335, United States
Clinical Research of West Florida, Inc /ID# 206146
Clearwater, Florida, 33765, United States
Revival Research /ID# 208383
Doral, Florida, 33122-1902, United States
Universal Axon Clinical Research /ID# 213703
Doral, Florida, 33166, United States
Lakes Research, LLC /ID# 209156
Miami, Florida, 33014, United States
Miami Dade Medical Research Institute /ID# 209413
Miami, Florida, 33176, United States
Savin Medical Group, LLC /ID# 206902
Miami Lakes, Florida, 33014-2490, United States
Floridian Clinical Research /ID# 207433
Miami Lakes, Florida, 33016-1842, United States
Advanced Research for Health Improvement /ID# 217987
Naples, Florida, 34102-5430, United States
Advanced Research for Health Improvement /ID# 218003
Naples, Florida, 34102-5430, United States
Complete Health Research /ID# 213459
Ormond Beach, Florida, 32174-6302, United States
Precision Clinical Research /ID# 207364
Sunrise, Florida, 33351-7311, United States
Clinical Research Trials of Florida, Inc. /ID# 206840
Tampa, Florida, 33607, United States
ForCare Clinical Research /ID# 205120
Tampa, Florida, 33613-1244, United States
Georgia Pollens Clinical Research Centers, Inc /ID# 218567
Albany, Georgia, 31707-1282, United States
Marietta Dermatology Clinical Research /ID# 210317
Marietta, Georgia, 30060-1047, United States
Agile Clinical Research Trials /ID# 218080
Sandy Springs, Georgia, 30342, United States
Treasure Valley Medical Research /ID# 210298
Boise, Idaho, 83706, United States
Great Lakes Clinical Trials /ID# 205830
Chicago, Illinois, 60640, United States
Ashira Dermatology /ID# 205512
Gurnee, Illinois, 60031-3393, United States
Clinical Investigation Specialists, Inc. /ID# 206898
Gurnee, Illinois, 60031, United States
Northshore University Health System Dermatology Clinical Trials Unit /ID# 205135
Skokie, Illinois, 60077, United States
Raga Clinical Studies, LLC. /ID# 206749
Crown Point, Indiana, 46307, United States
Hutchinson Clinic /ID# 205970
Hutchinson, Kansas, 67502-1131, United States
Continental Clinical Solutions /ID# 210327
Towson, Maryland, 21204, United States
Beacon Clinical Research, LLC /ID# 206894
Quincy, Massachusetts, 02169, United States
David Fivenson, MD, PLC /ID# 206903
Ann Arbor, Michigan, 48103, United States
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 206895
Ann Arbor, Michigan, 48109, United States
Allergy, Asthma & Immunology Associates, PC /ID# 218169
Lincoln, Nebraska, 68505-2343, United States
Skin Specialists, PC /ID# 205515
Omaha, Nebraska, 68144, United States
Duplicate_Summit Medical Group /ID# 213863
Clifton, New Jersey, 07012-1647, United States
Skin Laser and Surgery Specialists of NY and NJ /ID# 206754
Hackensack, New Jersey, 07601-1997, United States
Care Access Research /ID# 218476
Hoboken, New Jersey, 07030-2757, United States
University of New Mexico School of Medicine /ID# 206756
Albuquerque, New Mexico, 87131-0001, United States
Fordham Dermatology /ID# 218508
The Bronx, New York, 10458-5046, United States
PMG Research of Wilmington LLC /ID# 205968
Wilmington, North Carolina, 28401, United States
University Hospitals Case Medical Center /ID# 206639
Cleveland, Ohio, 44106, United States
Awasty Research Network, LLC /ID# 206748
Marion, Ohio, 43302-6225, United States
Southside Dermatology /ID# 214451
Tulsa, Oklahoma, 74132, United States
Vital Prospects Clinical Research Institute, PC /ID# 205824
Tulsa, Oklahoma, 74136-7049, United States
Cyn3rgy Research /ID# 218064
Gresham, Oregon, 97030-8316, United States
Velocity Clinical Research Hallandale Beach /ID# 207544
Medford, Oregon, 97504, United States
Clinical Research Solutions, LLC /ID# 218416
Jackson, Tennessee, 38305-2163, United States
Stones River Dermatology /ID# 205178
Murfreesboro, Tennessee, 37129-3194, United States
Metroplex Dermatology /ID# 213307
Arlington, Texas, 76014-3105, United States
Bellaire Dermatology /ID# 205470
Bellaire, Texas, 77401, United States
Center for Clinical Studies /ID# 213186
Cypress, Texas, 77433, United States
Dermatology Treatment and Research Center, PA /ID# 205473
Dallas, Texas, 75230, United States
Epiphany Dermatology - Fort Worth /ID# 210073
Fort Worth, Texas, 76244-6548, United States
Styde Research, LLC /ID# 213469
Lewisville, Texas, 75067, United States
Austin Institute for Clinical Research /ID# 206640
Pflugerville, Texas, 78660, United States
Derm Clin Res Ctr San Antonio /ID# 205469
San Antonio, Texas, 78229, United States
EPIC Medical Research /ID# 206382
Murray, Utah, 84123-5632, United States
Aspen Clinical Research /ID# 208399
Orem, Utah, 84058, United States
Timber Lane Allergy & Asthma Research, LLC /ID# 206897
South Burlington, Vermont, 05403-7204, United States
The Education & Research Foundation, Inc. /ID# 206900
Lynchburg, Virginia, 24501-1403, United States
Bellingham Asthma Allergy and Immunology Clinic /ID# 210357
Bellingham, Washington, 98225-1945, United States
Clinical Investigation Specialist, Inc - Kenosha /ID# 215933
Kenosha, Wisconsin, 53144-1782, United States
The Skin Hospital /ID# 217846
Westmead, New South Wales, 2145, Australia
The Skin Centre /ID# 205922
Benowa, Queensland, 4217, Australia
Box Hill Hospital /ID# 206023
Box Hill, Victoria, 3128, Australia
Monash Children's Hospital /ID# 217917
Clayton, Victoria, 3168, Australia
Sinclair Dermatology /ID# 217791
East Melbourne, Victoria, 3002, Australia
The Royal Melbourne Hospital /ID# 205919
Parkville, Victoria, 3050, Australia
Murdoch Children's Research Institute /ID# 205667
Parkville, Victoria, 3052, Australia
Universitaetsklinikum St. Poelten /ID# 206909
Sankt Pölten, Lower Austria, 3100, Austria
Ordensklinikum Linz GmbH Elisabethinen /ID# 206573
Linz, Upper Austria, 4010, Austria
Klinik Donaustadt /ID# 206572
Vienna, Vienna, 1220, Austria
Landeskrankenhaus Salzburg-Universitätsklinikum der PMU (LKH) /ID# 208281
Salzburg, 5020, Austria
UCL Saint-Luc /ID# 205537
Woluwe-Saint-Lambert, Brussels Capital, 1200, Belgium
UZ Gent /ID# 205181
Ghent, Oost-Vlaanderen, 9000, Belgium
Centre Hospitalier Universitaire du Sart Tilman CHU de Liege /ID# 204938
Liège, 4000, Belgium
Medical center Sveti Panteleimon /ID# 210414
Sofia, 1000, Bulgaria
Acibadem City Clinic Tokuda University Hospital EAD /ID# 205292
Sofia, 1407, Bulgaria
Military Medical Academy Multiprofile Hospital /ID# 205291
Sofia, 1606, Bulgaria
Medical complex Doverie /ID# 211289
Sofia, 1632, Bulgaria
Stratica Medical /ID# 205415
Edmonton, Alberta, T5K 1X3, Canada
Alberta DermaSurgery Centre /ID# 205422
Edmonton, Alberta, T6G 1C3, Canada
UBC Department of Dermatology and Skin Science The Skin Care Centre /ID# 207837
Vancouver, British Columbia, V5Z 4E8, Canada
Pacific Derm /ID# 206797
Vancouver, British Columbia, V6H 4E1, Canada
Skin Care Studio /ID# 205420
St. John's, Newfoundland and Labrador, A1E 1V4, Canada
SimcoDerm Medical and Surgical Dermatology Center /ID# 206333
Barrie, Ontario, L4M 7G1, Canada
Kingsway Clinical Research /ID# 206005
Etobicoke, Ontario, M8X 1Y9, Canada
Dr. Lyne Giroux Medicine Professional Corporation /ID# 206771
Greater Sudbury, Ontario, P3C 1X8, Canada
Dr. Dusan Sajic Medicine Professional Corporation /ID# 206890
Guelph, Ontario, N1L 0B7, Canada
The Guenther Dermatology Research Centre /ID# 206772
London, Ontario, N6A 3H7, Canada
DermEdge Research Inc. /ID# 206036
Mississauga, Ontario, L5H 1G9, Canada
Dr. S.K. Siddha Medicine Professional Corporation /ID# 207138
Newmarket, Ontario, L3Y 5G8, Canada
Allergy Research Canada Inc. /ID# 213547
Niagara Falls, Ontario, L2H 1H5, Canada
Niakosari Medicine Professional Corporation /ID# 206004
Toronto, Ontario, M2M 4J5, Canada
Skinsense Medical Research /ID# 206873
Saskatoon, Saskatchewan, S7K 0H6, Canada
DermaPlus - Poliklinika za dermatologiju i venerologiju /ID# 205429
Zagreb, City of Zagreb, 10000, Croatia
Djecja bolnica Srebrnjak /ID# 205926
Zagreb, City of Zagreb, 10000, Croatia
Poliklinika Vlatka Cavka d.o.o. /ID# 211126
Zagreb, City of Zagreb, 10000, Croatia
Naftalan - Specijalna bolnica za medicinsku rehabilitaciju /ID# 203448
Ivanić-Grad, Zagreb County, 10310, Croatia
Fakultni nemocnice Plzen /ID# 205096
Pilsen, 305 99, Czechia
Sanatorium profesora Arenbergera /ID# 205098
Prague, 110 00, Czechia
Vseobecna fakultni nemocnice v Praze /ID# 205201
Prague, 128 08, Czechia
Fakultni Nemocnice v Motole /ID# 218192
Prague, 150 06, Czechia
Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o. z. /ID# 205097
Ústí nad Labem, 400 11, Czechia
Aarhus University Hospital /ID# 205524
Aarhus N, Central Jutland, 8200, Denmark
Sjællands Universitetshospital /ID# 205960
Roskilde, Region Sjælland, 4000, Denmark
Hopital Saint-Andre /ID# 206554
Bordeaux, 33075, France
CHRU de Brest - Hopital Morvan /ID# 206555
Brest, 29200, France
C.H. de Bretagne Sud /ID# 206910
Lorient, 56322, France
AP-HP - Hopital Saint-Louis /ID# 206552
Paris, 75010, France
Hopital Prive d'Antony /ID# 206553
Antony, Île-de-France Region, 92160, France
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 206658
Kiel, Schleswig-Holstein, 24105, Germany
Klinikum Darmstadt /ID# 207483
Darmstadt, 64283, Germany
Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 205767
Dresden, 01307, Germany
Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 207982
Hamburg, 20246, Germany
Dermatologische Gemeinschaftspraxis Mahlow /ID# 205765
Mahlow, 15831, Germany
Haut- und Laserzentrum Hunsrück /ID# 205768
Simmern, 55469, Germany
Hautarztpraxis Dr. med. Matthias Hoffmann /ID# 205766
Witten, 58453, Germany
CentroDerm GmbH /ID# 206861
Wuppertal, 42287, Germany
251 Airforce General Hospital /ID# 205841
Athens, Attica, 11525, Greece
401 GSNA - 401 Army General Hospital /ID# 205352
Athens, Attica, 11525, Greece
General Hospital Andreas Syggros /ID# 204527
Athens, Attica, 16121, Greece
Papageorgiou General Hospital Thessaloniki /ID# 204526
Stavroupoli (Thessalonikis), Thessaloniki, 55536, Greece
Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 218072
Miskolc, Borsod-Abauj Zemplen county, 3526, Hungary
Bugat Pal Korhaz /ID# 211247
Gyöngyös, Heves County, 3200, Hungary
Somogy Megyei Kaposi Mor Oktato Korhaz /ID# 205611
Kaposvár, Somogy County, 7400, Hungary
Drug Research Center /ID# 217855
Balatonfüred, Veszprém megye, 8230, Hungary
Clinexpert Kft /ID# 211246
Budapest, 1033, Hungary
Synexus Magyarorszag Kft. /ID# 206008
Budapest, 1036, Hungary
Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 205085
Pécs, 7624, Hungary
St James Hospital /ID# 204264
Dublin, Dublin, D08 NHY1, Ireland
South Infirmary Victoria University Hospital /ID# 204265
Cork, T12 X23H, Ireland
University Hospital Galway /ID# 209965
Galway, H91 YR71, Ireland
University Hospital Waterford /ID# 204266
Waterford, X91 ER8E, Ireland
IRCCS Istituti Fisioterapici Ospitalieri-Istituto Dermatologico San Gallicano /ID# 205986
Rome, Lazio, 00144, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 205987
Rome, Lazio, 00168, Italy
ASST Spedali civili di Brescia /ID# 205927
Brescia, 25123, Italy
Azienda Ospedaliero Universitaria di Cagliari- Presidio Ospedaliero /ID# 205168
Cagliari, 09124, Italy
Presidio Ospedaliero San Salvatore /ID# 205167
L’Aquila, 67100, Italy
Azienda Ospedaliero-Universitaria di Modena /ID# 205169
Modena, 41124, Italy
Bravis Ziekenhuis /ID# 206676
Bergen op Zoom, North Brabant, 4624 VT, Netherlands
Centrum Oosterwal /ID# 209640
Alkmaar, 1817 MS, Netherlands
Reinier de Graaf /ID# 205811
Delft, 2625 AD, Netherlands
Universitair Medisch Centrum Groningen /ID# 205162
Groningen, 9713 GZ, Netherlands
Greenlane Clinical Centre /ID# 205664
Epsom, Auckland, 1051, New Zealand
CCA Braga - Hospital de Braga /ID# 205854
Braga, 4710-243, Portugal
Centro Hospitalar de Leiria, EPE /ID# 209906
Leiria, 2410-197, Portugal
Centro Hospitalar Universitário de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 205839
Lisbon, 1649-035, Portugal
Hospital CUF Descobertas /ID# 205431
Lisbon, 1998-018, Portugal
CHP, EPE- Hospital Geral de Sa /ID# 205187
Porto, 4050, Portugal
Centro Hospitalar Universitario de Sao Joao, EPE /ID# 205679
Porto, 4200-319, Portugal
National Skin Centre /ID# 205222
Singapore, Central Singapore, 308205, Singapore
National University Hospital /ID# 205224
Singapore, 119074, Singapore
Singapore General Hospital /ID# 205225
Singapore, 169608, Singapore
KK Women's & Children Hospital /ID# 206693
Singapore, 229899, Singapore
Changi General Hospital /ID# 205223
Singapore, 529889, Singapore
Korea University Ansan Hospital /ID# 206342
Ansan, Gyeonggido, 15355, South Korea
SoonChunHyang University Buchon Hospital /ID# 206391
Habun, Gyeonggido, 14584, South Korea
Ajou University Hospital /ID# 206341
Suwon, Gyeonggido, 16499, South Korea
The Catholic University of Korea Incheon St.Mary's Hospital /ID# 206529
Incheon, 21431, South Korea
Seoul National University Hospital /ID# 206396
Seoul, 03080, South Korea
Chung-Ang University Hostipal /ID# 206397
Seoul, 06973, South Korea
Hallym University Kangnam Sacred Heart Hospital /ID# 206343
Seoul, 07441, South Korea
Hospital Sant Joan de Deu /ID# 218047
Esplugues de Llobregat, Barcelona, 08950, Spain
Hospital Vital Alvarez Buylla /ID# 205770
Mieres, Principality of Asturias, 33611, Spain
Hospital Parc de Salut del Mar /ID# 204709
Barcelona, 08003, Spain
Hospital Clinic de Barcelona /ID# 210564
Barcelona, 08036, Spain
Hospital Universitario Reina Sofia /ID# 204712
Córdoba, 14004, Spain
Hospital Campus de la Salud /ID# 205544
Granada, 18016, Spain
Hospital General Universitario Gregorio Maranon /ID# 204380
Madrid, 28007, Spain
Hospital Infantil Universitario Nino Jesus /ID# 210437
Madrid, 28009, Spain
Hospital Universitario Infanta Leonor /ID# 204710
Madrid, 28031, Spain
Hospital General Universitario de Valencia /ID# 210565
Valencia, 46014, Spain
Taipei Medical University Shuang Ho Hospital /ID# 204804
New Taipei City, 23561, Taiwan
Chung Shan Medical University Hospital /ID# 205092
Taichung, 40201, Taiwan
National Taiwan University Hospital /ID# 204803
Taipei, 100, Taiwan
Linkou Chang Gung Memorial Ho /ID# 204783
Taoyuan, 333, Taiwan
University Hospital Southampton NHS Foundation Trust /ID# 205711
Southampton, Hampshire, SO16 6YD, United Kingdom
Northwick Park Hospital /ID# 205250
Middlesex, Harrow, HA1 3UJ, United Kingdom
Barts Health NHS Trust /ID# 206491
London, London, City of, E1 2ES, United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 204993
Newcastle upon Tyne, NE7 7DN, United Kingdom
University Hospital Plymouth NHS Trust /ID# 204649
Plymouth, PL6 8DH, United Kingdom
Related Publications (14)
Irvine AD, Prajapati VH, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Gold LFS, de Bruin-Weller M, Bieber T, Kabashima K, Rosmarin D, Sancho C, Calimlim BM, Grada A, Yang Y, Wu X, Levy G, Raymundo EM, Teixeira HD, Silverberg JI. Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. Am J Clin Dermatol. 2025 Nov;26(6):1003-1016. doi: 10.1007/s40257-025-00975-3. Epub 2025 Sep 3.
PMID: 40900410DERIVEDBurmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28.
PMID: 40875187DERIVEDSilverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Glick B, Staubach P, Calimlim B, Li C, Grada A, Moreira A, Lee WJ, Wollenberg A. Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2). Dermatol Ther (Heidelb). 2025 Sep;15(9):2583-2594. doi: 10.1007/s13555-025-01485-0. Epub 2025 Jul 14.
PMID: 40658277DERIVEDSimpson EL, Silverberg JI, Prajapati VH, Eyerich K, Katoh N, Boguniewicz M, Guttman-Yassky E, Song EJ, Lee WJ, Teixeira HD, Wu T, Sancho Sanchez C, Vigna N, Calimlim BM, de Bruin-Weller M. Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). 2025 Aug;15(8):2061-2076. doi: 10.1007/s13555-025-01443-w. Epub 2025 Jun 2.
PMID: 40457140DERIVEDPaller AS, Mendes-Bastos P, Siegfried E, Eichenfield LF, Soong W, Prajapati VH, Lio P, Simpson EL, Raymundo EM, Suravaram S, Hu X, Yang Y, Huang X, Calimlim BM, Platt AM, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks. JAMA Dermatol. 2024 Dec 1;160(12):1304-1313. doi: 10.1001/jamadermatol.2024.3696.
PMID: 39441580DERIVEDBlauvelt A, Eyerich K, Irvine AD, de Bruin-Weller M, Kwatra SG, Gooderham M, Kim B, Calimlim BM, Lee WJ, Raymundo EM, Liu Y, Ofori S, Platt AM, Silverberg JI. More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis. Dermatol Ther (Heidelb). 2024 Sep;14(9):2621-2630. doi: 10.1007/s13555-024-01242-9. Epub 2024 Aug 7.
PMID: 39110139DERIVEDSimpson EL, Prajapati VH, Leshem YA, Chovatiya R, de Bruin-Weller MS, Stander S, Pink AE, Calimlim BM, Lee WJ, Teixeira H, Ladizinski B, Hu X, Yang Y, Liu Y, Liu M, Grada A, Platt AM, Silverberg JI. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2). Dermatol Ther (Heidelb). 2024 May;14(5):1127-1144. doi: 10.1007/s13555-024-01157-5. Epub 2024 May 2.
PMID: 38696027DERIVEDSilverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, Hijnen D, Calimlim BM, Lee WJ, Teixeira HD, Hu X, Zhang S, Yang Y, Grada A, Platt AM, Thaci D. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). Am J Clin Dermatol. 2024 May;25(3):485-496. doi: 10.1007/s40257-024-00853-4. Epub 2024 Mar 25.
PMID: 38528257DERIVEDThyssen JP, Thaci D, Bieber T, Gooderham M, de Bruin-Weller M, Soong W, Kabashima K, Barbarot S, Luna PC, Xu J, Hu X, Liu Y, Raymundo EM, Calimlim BM, Nduaka C, Gamelli A, Simpson EL. Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1871-1880. doi: 10.1111/jdv.19232. Epub 2023 Jun 21.
PMID: 37247226DERIVEDPaller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391.
PMID: 37043227DERIVEDBurmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735.
PMID: 36754548DERIVEDMendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15.
PMID: 35714786DERIVEDSimpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, Calimlim BM, Thyssen JP, Chiou AS, Bissonnette R, Stein Gold LF, Wegzyn C, Hu X, Liu M, Liu J, Tenorio AR, Chu AD, Guttman-Yassky E. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029.
PMID: 35262646DERIVEDGuttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaci D, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21.
PMID: 34023008DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Global Medical Services
- Organization
- AbbVie
Study Officials
- STUDY DIRECTOR
ABBVIE INC.
AbbVie
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
- Expanded Access
- Yes
Study Record Dates
First Submitted
July 25, 2018
First Posted
July 31, 2018
Study Start
July 27, 2018
Primary Completion
March 11, 2021
Study Completion
November 11, 2025
Last Updated
December 3, 2025
Results First Posted
March 28, 2022
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- For details on when studies are available for sharing, please refer to the link below.
- Access Criteria
- Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.